EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent advances in neuroimaging of Alzheimer's disease and related dementias

Julie Ottoy iD, Nicole Owsicki, Murat Bilgel, Alexa Pichet Binette, Gemma Salvadó, Min Su Kang, David M Cash, Michael Ewers, Renaud La Joie, Laura E M Wisse, Maged Goubran, Tobey Betthauser

Alzheimer's & Dementia · 2025-09 · 21 (9)

DOI: 10.1002/alz.70648 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 08.09.2025. Verfasst von Julie Ottoy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Black Centre for Brain Resilience & Recovery, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroimaging, Brain, Dementia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ERAPerMed, Alzheimerfonden, Strategic Research Area MultiPark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review covers recent advances (2023–2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood‐based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain. We examine the utility of neuroimaging for (1) tracking the spatiotemporal progression of pathology, (2) serving as the reference standard for validating novel fluid biomarkers, (3) characterizing disease heterogeneity, (4) exploring the role of brain networks in ADRD progression, and (5) evaluating biomarkers for better individualized estimates of treatment benefit. Finally, we discuss advances in radiotracer development and AD risk factors. By reviewing the most promising breakthroughs in the neuroimaging field, we hope to spark new ideas for future discoveries that will deepen our understanding of ADRD. Highlights The diagnostic and staging criteria for Alzheimer's disease (AD) were updated in 2024. Despite robust harmonization methods for amyloid beta positron emission tomography (PET), parallel efforts for tau PET remain challenging. Larger anti‐amyloid drug effects were seen at lower levels of amyloid and tau PET. Phosphorylated tau217 (p‐tau217) is currently the most promising plasma biomarker to detect AD pathology. There are new tracer developments for alpha‐synuclein, primary tauopathies, and inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeuroimagingBrainDementiaHumansBiomarkersPositron-Emission TomographyDisease Progressiontau Proteins

Stichwörter der Autor:innen

Alzheimer's diseaseamyloidcerebrospinal fluid biomarkercerebrovascular diseaseclinical trialsconnectivityco‐pathologydisease staging and subtypingheterogeneityinflammationneuroimagingplasma biomarkerpositron emission tomographyrisk factorstau

Substanzen

Biomarkerstau Proteins

Autor:innen und Institutionen

  • Black Centre for Brain Resilience & Recovery, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
  • Physical Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medicine (Neurology), University of Toronto, Toronto, Ontario, Canada.
  • Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, USA.
  • Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, University of Montréal, Montréal, Quebec, Canada.
  • Department of Clinical Sciences in Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.

ORCID-Profile: Julie Ottoy

Förderung

  • ERAPerMed
  • Alzheimerfonden
  • Strategic Research Area MultiPark
  • European Union's Horizon 2020 Research and Innovation Program
  • Canadian Institutes for Health Research
  • National Institutes of Health National Institute on Aging
  • NIA NIH HHS
  • Alzheimer's Association

Zitieren

APA

Ottoy, J., Owsicki, N., Bilgel, M., Binette, A. P., Salvadó, G., Kang, M. S., Cash, D. M., Ewers, M., La Joie, R., Wisse, L. E. M., Goubran, M., & Betthauser, T. (2025). Recent advances in neuroimaging of Alzheimer's disease and related dementias. Alzheimer's & Dementia, 21(9). https://doi.org/10.1002/alz.70648

Vancouver

Ottoy J, Owsicki N, Bilgel M, Binette AP, Salvadó G, Kang MS, et al. Recent advances in neuroimaging of Alzheimer's disease and related dementias. Alzheimer's & Dementia. 2025;21(9). doi:10.1002/alz.70648

BibTeX
@article{Ottoy2025,
  author = {Ottoy, Julie and Owsicki, Nicole and Bilgel, Murat and Binette, Alexa Pichet and Salvadó, Gemma and Kang, Min Su and Cash, David M and Ewers, Michael and La Joie, Renaud and Wisse, Laura E M and Goubran, Maged and Betthauser, Tobey},
  title = {Recent advances in neuroimaging of Alzheimer's disease and related dementias},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {9},
  doi = {10.1002/alz.70648}
}
Kostenlos starten →